Multiplatform untargeted metabolomics
- PMID: 37005774
- PMCID: PMC10948111
- DOI: 10.1002/mrc.5350
Multiplatform untargeted metabolomics
Abstract
Metabolomics samples like human urine or serum contain upwards of a few thousand metabolites, but individual analytical techniques can only characterize a few hundred metabolites at best. The uncertainty in metabolite identification commonly encountered in untargeted metabolomics adds to this low coverage problem. A multiplatform (multiple analytical techniques) approach can improve upon the number of metabolites reliably detected and correctly assigned. This can be further improved by applying synergistic sample preparation along with the use of combinatorial or sequential non-destructive and destructive techniques. Similarly, peak detection and metabolite identification strategies that employ multiple probabilistic approaches have led to better annotation decisions. Applying these techniques also addresses the issues of reproducibility found in single platform methods. Nevertheless, the analysis of large data sets from disparate analytical techniques presents unique challenges. While the general data processing workflow is similar across multiple platforms, many software packages are only fully capable of processing data types from a single analytical instrument. Traditional statistical methods such as principal component analysis were not designed to handle multiple, distinct data sets. Instead, multivariate analysis requires multiblock or other model types for understanding the contribution from multiple instruments. This review summarizes the advantages, limitations, and recent achievements of a multiplatform approach to untargeted metabolomics.
Keywords: mass spectrometry; metabolite assignment; metabolome coverage; metabolomics; multiplatform; nuclear magnetic resonance.
© 2023 The Authors. Magnetic Resonance in Chemistry published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors declare no competing financial interest.
Figures










Similar articles
-
The combination of four analytical methods to explore skeletal muscle metabolomics: Better coverage of metabolic pathways or a marketing argument?J Pharm Biomed Anal. 2018 Jan 30;148:273-279. doi: 10.1016/j.jpba.2017.10.013. Epub 2017 Oct 18. J Pharm Biomed Anal. 2018. PMID: 29059617
-
Untargeted HILIC-MS-Based Metabolomics Approach to Evaluate Coffee Roasting Process: Contributing to an Integrated Metabolomics Multiplatform.Molecules. 2020 Feb 17;25(4):887. doi: 10.3390/molecules25040887. Molecules. 2020. PMID: 32079306 Free PMC article.
-
New and vintage solutions to enhance the plasma metabolome coverage by LC-ESI-MS untargeted metabolomics: the not-so-simple process of method performance evaluation.Anal Chem. 2015 Mar 3;87(5):2639-47. doi: 10.1021/ac503031d. Epub 2015 Feb 16. Anal Chem. 2015. PMID: 25642801
-
Promises and pitfalls of untargeted metabolomics.J Inherit Metab Dis. 2018 May;41(3):355-366. doi: 10.1007/s10545-017-0130-7. Epub 2018 Mar 13. J Inherit Metab Dis. 2018. PMID: 29536203 Free PMC article. Review.
-
Metabolomics in chronic kidney disease: Strategies for extended metabolome coverage.J Pharm Biomed Anal. 2018 Nov 30;161:313-325. doi: 10.1016/j.jpba.2018.08.046. Epub 2018 Aug 25. J Pharm Biomed Anal. 2018. PMID: 30195171 Review.
Cited by
-
Metabolomics and Lipidomics for Studying Metabolic Syndrome: Insights into Cardiovascular Diseases, Type 1 & 2 Diabetes, and Metabolic Dysfunction-Associated Steatotic Liver Disease.Physiol Res. 2024 Aug 30;73(S1):S165-S183. doi: 10.33549/physiolres.935443. Physiol Res. 2024. PMID: 39212142 Free PMC article. Review.
-
The Application of Metabolomics in Hyperlipidemia: Insights into Biomarker Discovery and Treatment Efficacy Assessment.Metabolites. 2024 Aug 6;14(8):438. doi: 10.3390/metabo14080438. Metabolites. 2024. PMID: 39195534 Free PMC article. Review.
-
Relationship between circulating metabolites and diabetic retinopathy: a two-sample Mendelian randomization analysis.Sci Rep. 2024 Feb 29;14(1):4964. doi: 10.1038/s41598-024-55704-3. Sci Rep. 2024. PMID: 38424453 Free PMC article.
-
Metabolomic machine learning-based model predicts efficacy of chemoimmunotherapy for advanced lung squamous cell carcinoma.Front Immunol. 2025 Apr 2;16:1545976. doi: 10.3389/fimmu.2025.1545976. eCollection 2025. Front Immunol. 2025. PMID: 40242771 Free PMC article.
-
Simulated LC-MS Data Set for Assessing the Metabolomics Data Processing Pipeline Implemented into MVAPACK.Anal Chem. 2024 Aug 13;96(32):12943-12956. doi: 10.1021/acs.analchem.3c04979. Epub 2024 Jul 30. Anal Chem. 2024. PMID: 39078713 Free PMC article.
References
-
- Di Minno A, Gelzo M, Stornaiuolo M, Ruoppolo M, Castaldo G, Nutrition, Metabolism and Cardiovascular Diseases 2021, 31, 1645–1652. - PubMed
-
- Katam R, Lin C, Grant K, Katam CS, Chen S, International Journal of Molecular Sciences 2022, 23, 6985; - PMC - PubMed
- Jin L, Godri Pollitt KJ, Liew Z, Rosen Vollmar AK, Vasiliou V, Johnson CH, Zhang Y, Current Environmental Health Reports 2021, 8, 7–22; - PubMed
- Wei S, Wei Y, Gong Y, Chen Y, Cui J, Li L, Yan H, Yu Y, Lin X, Li G, Yi L, Metabolomics 2022, 18, 35. - PubMed
-
- Lacalle-Bergeron L, Izquierdo-Sandoval D, Sancho JV, López FJ, Hernández F, Portolés T, TrAC Trends in Analytical Chemistry 2021, 135, 116161;
- Jacobs DM, van den Berg MA, Hall RD, Current Opinion in Biotechnology 2021, 70, 23–28. - PubMed
-
- Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, Srivas R, Palsson BØ, Proceedings of the National Academy of Sciences 2007, 104, 1777–1782; - PMC - PubMed
- Graham E, Lee J, Price M, Tarailo-Graovac M, Matthews A, Engelke U, Tang J, Kluijtmans LAJ, Wevers RA, Wasserman WW, van Karnebeek CDM, Mostafavi S, Journal of Inherited Metabolic Disease 2018, 41, 435–445. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources